The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Then, a company named Regeneron announced they would buy the company, and would “prioritize [consumer data's] privacy, ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

If approved by the court, the 23andMe sale would put Anne Wojcicki back at the helm of the company she co-founded and previously attempted to take private.

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

"It's cool to get the award, but what I submitted to it is so much more important to me," Cooper Taylor said about getting a ...